Valuation : China Shineway Pharmaceutical Group Limited

Market Cap 5.14B 766M 660M 625M 566M 1.06B 73.15B 1.07B 7.42B 2.85B 37.22B 2.88B 2.81B 118B P/E 2026 *
6.8x
P/E 2027 * 6.33x
Enterprise Value 5.14B 766M 660M 625M 566M 1.06B 73.15B 1.07B 7.42B 2.85B 37.22B 2.88B 2.81B 118B EV / Sales 2026 *
2.19x
EV / Sales 2027 * 2.19x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
3 years 18.53
Extreme 18.53
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 01/12/2019
Comptroller/Controller/Auditor 53 01/02/2011
Director TitleAgeSince
Chairman 70 14/08/2002
Director/Board Member 62 14/08/2002
Director/Board Member 58 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.89%-.--% - - 766M
-1.13%-3.11%+13.82%+60.66% 46.21B
-1.13%-5.78%+33.26%+108.13% 38.78B
+0.12%-0.08%+7.12%+78.27% 11.68B
-0.53%-1.37%-13.25%+10.18% 11.55B
-0.38%-2.26%+18.18%+139.63% 9.14B
+0.32%-2.26%+23.08%+34.73% 7.3B
+0.17%-0.74%+13.44%+197.13% 7.15B
-1.00%-5.25%+34.34%-19.63% 7.1B
-3.13%-4.30%-44.88%+11.66% 4.97B
Average -0.28%-2.59%+9.46%+68.97% 15.99B
Weighted average by Cap. -0.83%-3.27%+16.06%+75.66%

Financials

2026 *2027 *
Net sales 2.34B 349M 301M 285M 258M 485M 33.38B 487M 3.39B 1.3B 16.98B 1.31B 1.28B 53.66B 2.35B 350M 301M 285M 259M 485M 33.42B 488M 3.39B 1.3B 17B 1.31B 1.29B 53.73B
Net income 755M 113M 96.96M 91.81M 83.22M 156M 10.75B 157M 1.09B 419M 5.47B 423M 413M 17.28B 811M 121M 104M 98.62M 89.39M 168M 11.55B 169M 1.17B 450M 5.88B 454M 444M 18.57B
Net Debt - -
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,822
Date Price Change
11/09/26 $0.000000 -
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.800CNY
Average target price
7.294CNY
Spread / Average Target
+7.26%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!